Autosomal Dominant Optic Atrophy (ADOA) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Autosomal Dominant Optic Atrophy Emerging Therapy and TPP Insights

Thelansis’s “Autosomal Dominant Optic Atrophy (ADOA) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Autosomal Dominant Optic Atrophy Overview

Autosomal dominant optic atrophy (ADOA) is an inherited optic neuropathy most often caused by pathogenic OPA1 variants. Reduced OPA1 function disrupts mitochondrial dynamics and energy production, leaving retinal ganglion cells and their axons vulnerable to degeneration. It usually causes bilateral, often childhood-onset loss of central vision, impaired colour perception, and central or paracentral visual-field defects. Severity and progression vary; some people develop hearing, muscle, or neurological features. Care includes eye monitoring, genetic counselling, and low-vision support; no disease-modifying treatment is approved. Research is advancing: STK-002, an investigational antisense oligonucleotide designed to increase OPA1 protein, entered Phase 1 testing in 2026, while PYC-001 is in early clinical evaluation. Gene-replacement approaches are also under study. These treatments remain experimental, and their ability to preserve or improve vision awaits clinical results.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)